Article Information
History
- November 4, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- 1Corpometria Institute, Brasília, DF, Brazil
- 2Applied Biology Inc., Irvine, CA, USA
- 3Brown University, RI, USA
- ↵*Address correspondence: Flavio A. Cadegiani, MD, MSc, PhD, Division of Endocrinology and Metabolism, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Pedro de Toledo 781 – 13th floor, 04039-032 São Paulo, SP – Brazil, Email: flavio.cadegiani{at}unifesp.br; f.cadegiani{at}gmail.com, Telephone: +55 61 996506111, Fax: +55 61 33464733
Posted November 04, 2020.
Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
5
Blogs/Media
Author Videos